Collectively, our findings characterize a novel Myc-derived circRNA controlling TNBC tumorigenesis via regulation of metabolic reprogramming, implying a promising therapeutic target.
Myc derived circRNA promotes triple-negative breast cancer progression via reprogramming fatty acid metabolism.